Yankees Score with ...
Health Care: Drugs
PDL BioPharma Inc. (PDLI: NASDAQ)
$8.37 0.02 | 0.24%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 131.21M | 168.54M | 211.57M | 303.23M |
| Receivables | 7.87M | 600.00K | 469.00K | 1.05M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 5.95M | 0.00 |
| Total Current Assets | 182.98M | 233.51M | 284.66M | 315.84M |
| Property, Plant & Equipment, Gross | 9.19M | 9.14M | 9.14M | 9.14M |
| Accumulated Depreciation & Depletion | 9.13M | 9.12M | 9.06M | 8.97M |
| Property, Plant & Equipment, Net | 59.00K | 22.00K | 80.00K | 171.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 92.37M | 24.46M | 9.30M | 12.01M |
| Total Non-Current Assets | 96.98M | 35.96M | 32.00M | 22.58M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 279.97M | 269.47M | 316.67M | 338.41M |
| Accounts Payable | 1.07M | 528.00K | 2.54M | 370.00K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 287.00K | 0.00 | 20.00K | 0.00 |
| Total Current Liabilities | 10.47M | 133.01M | 193.99M | 293.52M |
| Long Term Debt | 309.95M | 316.62M | 395.45M | 450.15M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 27.66M | 24.12M | 51.41M | 10.70M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 337.61M | 340.74M | 446.86M | 460.85M |
| Total Liabilities | 348.09M | 473.74M | 640.85M | 754.36M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -68.12M | -204.27M | -324.18M | -415.95M |
| Common Par | 1.40M | 1.40M | 1.40M | 1.20M |
| Additional Paid In Capital | -234.07M | -161.75M | -87.37M | -83.85M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | 169.63M | -42.04M | -241.42M | -333.30M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -5.09M | -1.88M | 3.22M | 0.00 |
| Total Capitalization | 241.83M | 112.34M | 71.27M | 34.20M |
| Total Equity | -68.12M | -204.27M | -324.18M | -415.95M |
| Total Liabilities & Stock Equity | 279.97M | 269.47M | 316.67M | 338.41M |
| Total Common Shares Outstanding | 139.82M | 139.68M | 139.64M | 119.52M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 139.71M | 139.66M | 126.58M | 119.40M |
| Diluted Weighted Shares Outstanding | 146.40M | 177.44M | 178.80M | 184.40M |
| Number of Employees | 10 | 10 | 8 | 7 |
| Number of Part-Time Employees | 0 | 0 | 1 | 2 |
Portfolios with PDLI
- Portfolio NameUser Type
- ProHighbridge Capital Management
- ContributorEarnings Short Squeeze Play...
- UserSm. Magic July 5 13
- UserMy Stuff
- Userdgr008 Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- UserDividend
- Contributor18 Fundamentally Strong Sto...
- UserGK13
- UserMy current
Latest PDLI Headlines from TheStreet
- 'Mad Money' Lightning Round: Ford Is a Buy 05.16.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Google vs. Apple 05.15.13 | 07:05 pm
- 4 Buy-Rated Dividend Stocks: COP, ETE, PDLI, TEG 05.10.13 | 11:05 am
- 3 Buy-Rated Dividend Stocks 04.26.13 | 11:04 am
- PDL BioPharma (PDLI) Shares Cross Below 200 DMA 04.17.13 | 12:04 pm
- 5 Buy-Rated Dividend Stocks 04.16.13 | 11:04 am
- 3 Buy-Rated Dividend Stocks 04.04.13 | 11:04 am
- 2 Drug Stocks Under $10 To Pick As Favorites 03.25.13 | 02:03 pm
- 'Mad Money' Lightning Round: Stay Away From Intel 11.06.12 | 06:11 am
- Cramer's 'Mad Money' Recap: Politics Is Overrated 11.05.12 | 08:11 pm
Press Releases for PDLI
- PDL BioPharma To Announce First Quarter 2013 Financial Results On May 9, 2013 - PR Newswire 05.02.13 | 07:05 am
- PDL BioPharma Appoints Peter Garcia As Chief Financial Officer - PR Newswire 04.30.13 | 04:04 pm
- PDL BioPharma Completes Structured Financing And Royalty Transaction With Avinger - PR Newswire 04.22.13 | 12:04 pm
- PDL BioPharma Completes Regular Quarterly Dividend Payment - PR Newswire 03.12.13 | 04:03 pm
- PDL BioPharma To Hold Annual Meeting Of Stockholders On May 21, 2013 - PR Newswire 03.06.13 | 04:03 pm
- PDL BioPharma Announces Conversion Rate Adjustments For Convertible Notes - PR Newswire 03.04.13 | 07:03 am
- PDL BioPharma To Announce Fourth Quarter And Full Year 2012 Financial Results On March 1, 2013 - PR Newswire 02.25.13 | 04:02 pm
- PDL BioPharma To Present At Two Upcoming Investor Conferences - PR Newswire 02.20.13 | 07:02 am
- PDL BioPharma Announces 2013 Regular Quarterly Dividends - PR Newswire 01.30.13 | 07:01 am
- PDL BioPharma Announces Departure Of Finance VP - PR Newswire 01.30.13 | 06:01 am
Partner Headlines for PDLI
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- After-Hours Earnings Report for March 1, 2013 : VNR, PDLI - NASDAQ 03.01.13 | 07:03 pm
- PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 01, 2013 - NASDAQ 02.27.13 | 02:02 pm
- 8 High-Yielding Dividend Stocks With Very Low PEG Ratios - Seeking Alpha 12.30.12 | 09:12 am
- PDL BioPharma, AxoGen Benefit From 'Royal' Agreement - Seeking Alpha 11.20.12 | 09:11 am
- UPDATE: Credit Suisse Initiates PDL Biopharma at Neutral on Dividend Continuity Questions - Benzinga 11.13.12 | 01:11 pm
- These 2 Cramer High-Yield Picks Are Worth Buying In The Market Pullback - Seeking Alpha 11.08.12 | 09:11 am
- Cramer's Lightning Round - Heckmann Is Still A Good Spec (9/28/12) - Seeking Alpha 09.30.12 | 07:09 am
- PDLI Guides Q3 Royalty Rev to $85M - Analyst Blog - NASDAQ 09.07.12 | 08:09 pm
- PDL BioPharma Beats Zacks Estimates - Analyst Blog - Zacks 08.06.12 | 09:08 am
